The total consolidated income of the company has increased by 13.92% at Rs 1,197.01 crore for Q1FY27

The said acquisition is expected to be completed by August 31, 2026

These accreditations will enable the company to cater to EU regulated markets

The company has incorporated Wholly Owned Subsidiary namely ‘Akums Healthcare Malta’

The company had executed a Framework Agreement on August 22, 2025 with Government of the Republic of Zambia to establish a local manufacturing facility in Zambia

The facility, in the future, also plans to export to neighboring countries including, but not limited to, Zimbabwe, Namibia, Botswana, Malawi, Tanzania, Mozambique etc

The total consolidated income of the company increased by 12.43% at Rs 1073.09 crore for Q4FY25

The patent is valid for a term of 20 years

Total consolidated income of the company decreased by 6.12% at Rs 1024.97 crore for Q3FY25

This is in line with Akums growth objective of expanding in European and other regulated markets

This collaboration exclusively focuses on aseptic manufacturing and subsequent filling in carton packing for the RTD market

Akums has been granted the exclusive rights to sell certain Caregen products range, in India, during the term of the agreement

The company has entered into MoU for Local Manufacturing of Medicines

As per the terms of the agreement, Company has been granted the exclusive rights to further develop and market the products recently innovated by Triple Hair Inc, in the Territory of India

This product launch marks a step in commitment to innovation and providing high-quality healthcare solutions to the company’s customers

The company has received Patent Certificate on September 12, 2024, for its invention titled ‘Room Stable Hydroxyurea Oral Suspension’

The company is looking to raise Rs 136 crore through a pre-IPO placement